Fernando Jerkovich

Fernando Jerkovich

Auto-generated profile, based on publicly available information

Fernando Jerkovich

Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
ICInés Califano
Inés Califano
ASAnabella Smulever
Anabella Smulever
FJFernando Jerkovich
Fernando Jerkovich
FPFabian Pitoia
Fabian Pitoia

28 November 2023 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
EAErika Abelleira
Erika Abelleira
FJFernando Jerkovich
Fernando Jerkovich

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
MZMaría Belén Zanchetta
María Belén Zanchetta
FJFernando Jerkovich
Fernando Jerkovich
SNSelva Nuñez
Selva Nuñez
YMYamile Mocarbel
Yamile Mocarbel
APAnalía Pignatta
Analía Pignatta
JZJosé Rubén Zanchetta
José Rubén Zanchetta
Some studies based on bone biopsy have demonstrated that in patients with tumor-induced osteomalacia (TIO) the mineralization process of the bone matrix is profoundly disturbed. However, the interrelationship between clinical and biochemical features and bone microarchitecture in this disease needs further analysis. With this purpose in mind, we set out three objectives: (i) to determine bone microarchitecture and estimated bone strength in a group of patients with tumor-induced osteomalacia using high-resolution peripheral quantitative computed tomography (HR-pQCT) and finite element analysis (FEA), (ii) to investigate correlations between duration of disease, biochemical features, bone density, HR-pQCT and FEA parameters, and (iii) to compare HR-pQCT and FEA parameters with a healthy control group. Ten patients with TIO were included. All patients had non-resolved disease. At the distal radius, all bone microarchitecture parameters were significantly affected in patients with TIO in comparison with healthy controls. At the distal tibia, all parameters were significantly impaired, except for trabecular thickness. All the parameters were more affected in the distal tibia than in the distal radius. Women with TIO (n = 7) had significantly lower bone strength parameters than healthy controls. In men (n = 3), bone strength parameters were significantly lower than in the control group at the distal tibia. Alkaline phosphatase levels exhibited a negative correlation with microarchitecture parameters, failure load, and stiffness. Higher levels of parathyroid hormone correlated with poorer microarchitecture parameters. We believe that in TIO, hormonal disturbances and the lack of mechanical stimulus specially converge to generate an extremely harmful combination for bone health. © 2021 American Society for Bone and Mineral Research (ASBMR).

24 April 2021 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
MZM.B. Zanchetta
M.B. Zanchetta
EGE. Giacoia
E. Giacoia
FJF. Jerkovich
F. Jerkovich
EFE. Fradinger
E. Fradinger

21 May 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
FJFernando Jerkovich
Fernando Jerkovich
SCSoledad Capalbo
Soledad Capalbo
EAErika Abelleira
Erika Abelleira
FPFabián Pitoia
Fabián Pitoia

30 April 2024 in JBMR Plus
Verified
Journal Article
Open access
PDF file
VFVanina Farias
Vanina Farias
FJFernando Jerkovich
Fernando Jerkovich
ABAndrea Morejón Barragán
Andrea Morejón Barragán
APAlejandro Pereyra
Alejandro Pereyra
MPMariana González Pernas
Mariana González Pernas
MZMaría Belén Zanchetta
María Belén Zanchetta
Data on long-term treatment regimens for preventing bone mineral density (BMD) loss that occurs after denosumab (Dmab) withdrawal are scarce. Our aim was to evaluate the long-term changes (12–36 months) in BMD and bone turnover markers in a group of postmenopausal women who had been treated with Dmab and received subsequent treatment with bisphosphonates. Secondary objectives were to evaluate factors associated with BMD loss, to compare the BMD change in patients who received oral vs intravenous bisphosphonates, and to assess the frequency of fragility fractures after Dmab discontinuation. The clinical data of 54 patients, 26 of whom had clinical and DXA assessments at 36 months, were analyzed. After 12 months, the mean LS BMD had decreased by 2.8% (±5.0), FN BMD by 1.9% (±5.8), and TH BMD by 1.9% (±3.7). After 36 months, LS BMD had decreased by 3.7% (±6.7), FN BMD by 2.5% (±7.1), and TH BMD by 3.6% (±5.2). C-terminal cross-linked telopeptide of type I collagen significantly increased during the first 12 months after Dmab withdrawal but then decreased at 36 months. BMD loss at 12 months was higher in patients with more than 30 months of Dmab treatment, but this difference was only statistically significant at FN (−3.3% vs −0.3%, P = .252 at LS, −3.3% vs 0.3%, P = .033 at FN, and −2.1% vs 0.9, P = .091 at TH). There were no statistically significant differences regarding the change in BMD at 12 and 36 months between oral and intravenous treatment. Seven patients suffered incidental vertebral fractures (clinical vertebral fractures: n = 6, morphometric fractures: n = 1) three of which were multiple. None of these patients were treated following international or institutional guidelines or recommendations. In summary, our study suggests that bisphosphonates can help maintain BMD for 36 months after Dmab discontinuation. In our real-life study, we examined 54 patients who received bisphosphonate treatment after stopping denosumab. Among them, 26 patients underwent long-term assessments. We found that after three years of sequential treatment with bisphosphonates, bone density loss was less than 4%, with most of the loss occurring within the first 12 months. This suggests that bisphosphonates can help maintain bone density in patients who discontinue denosumab.